Helus Pharma Unveils HLP003 Data at Psych Congress 2026 - HELP
• Helus Pharma presented new Phase 1/2a study data for its major depressive disorder candidate, HLP003, at Psych Congress 2026. • The company shared results regarding HLP003 and its broader program of NSAs, which are non-selective antidepressants. • These results provide early evidence for a potential new treatment market, though the FDA and Health Canada have not yet evaluated or confirmed the drug's efficacy.
biopharmawatch.com
![[MUST WATCH] NASA’s Psyche Spacecraft Turned a Mars Flyby Into a Stunning Tour of the Red Planet](/_next/image?url=https%3A%2F%2Fcdn.zmescience.com%2Fwp-content%2Fuploads%2F2026%2F07%2FE2_PIA26749_Psyche_Imager_Mars_Mosaic1_F247E.width-1320.jpg&w=1920&q=85)



